AZNAstraZenecaRunning, no new patients
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
Triple Negative Breast Neoplasms
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 923 (final count)
- Started
- Jun 25, 2019
- Main results expected
- Mar 16, 2026
- Fully finished
- Mar 16, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival (OS)
Measured over: The time from date of randomisation to the date of death due to any cause up to approximately 42 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03997123 · record last updated 2025-12-22 · checked 2026-11-09 15:47 UTC